A multi-omic biomarker signature in pre-treatment rectal tumours stratifies patients with different pathological responses to neoadjuvant treatment

Laura E. Kane; Croí E. Buckley; Rebecca M. O'Brien; Meghana S. Menon; Aisling B. Heeran; Xiaofei Yin; Timothy S. Nugent; Noel E. Donlon; John V Reynolds; Adnan Hafeez; Diarmuid S. O'Ríordáin; Robert A. Hannon; Paul Neary; Reza Kalbassi; Brian J. Mehigan; Paul H. McCormick; Cara Dunne; John O. Larkin; Lorraine Brennan; Michael E. Kelly; Jacintha O'Sullivan; Niamh Lynam-Lennon

doi:10.1002/ctm2.70576

Clinical and Translational Medicine ›› 2026, Vol. 16 ›› Issue (1) :e70576 DOI: 10.1002/ctm2.70576

COMMENTARY

A multi-omic biomarker signature in pre-treatment rectal tumours stratifies patients with different pathological responses to neoadjuvant treatment

Author information +

History +

PDF

Keywords

biomarkers / metabolomics / rectal cancer / therapy response / transcriptomics

Cite this article

Download citation ▾

Laura E. Kane, Croí E. Buckley, Rebecca M. O'Brien, Meghana S. Menon, Aisling B. Heeran, Xiaofei Yin, Timothy S. Nugent, Noel E. Donlon, John V Reynolds, Adnan Hafeez, Diarmuid S. O'Ríordáin, Robert A. Hannon, Paul Neary, Reza Kalbassi, Brian J. Mehigan, Paul H. McCormick, Cara Dunne, John O. Larkin, Lorraine Brennan, Michael E. Kelly, Jacintha O'Sullivan, Niamh Lynam-Lennon. A multi-omic biomarker signature in pre-treatment rectal tumours stratifies patients with different pathological responses to neoadjuvant treatment. Clinical and Translational Medicine, 2026, 16(1): e70576 DOI:10.1002/ctm2.70576

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.

[2]	Buckley CE, Yin X, Meltzer S, et al. Energy metabolism is altered in radioresistant rectal cancer. Int J Mol Sci. 2023; 24(8): 7082.

[3]	Lynam-Lennon N, Maher SG, Maguire A, et al. Altered mitochondrial function and energy metabolism is associated with a radioresistant phenotype in oesophageal adenocarcinoma. PLoS One. 2014; 9(6):e100738.

[4]	Saito RF, Andrade LNS, Bustos SO, Chammas R. Phosphatidylcholine-derived lipid mediators: the crosstalk between cancer cells and immune cells. Front Immunol. 2022; 13:768606.

[5]	Markowski AR, Blachnio-Zabielska AU, Pogodzinska K, Markowska AJ, Zabielski P. Diverse sphingolipid profiles in rectal and colon cancer. Int J Mol Sci. 2023; 24(13):10867.

[6]	Farber SA, Slack BE, Blusztajn JK. Acceleration of phosphatidylcholine synthesis and breakdown by inhibitors of mitochondrial function in neuronal cells: a model of the membrane defect of Alzheimer's disease. FASEB J. 2000; 14(14): 2198-2206.

[7]	Curtis JJ, Vo NTK, Seymour CB, Mothersill CE. 5-HT(2A) and 5-HT(3) receptors contribute to the exacerbation of targeted and non-targeted effects of ionizing radiation-induced cell death in human colon carcinoma cells. Int J Radiat Biol. 2020; 96(4): 482-490.

[8]	de Mey S, Dufait I, De Ridder M. Radioresistance of human cancers: clinical implications of genetic expression signatures. Front Oncol. 2021; 11:761901.

[9]	Siprashvili Z, Webster DE, Johnston D, et al. The noncoding RNAs SNORD50A and SNORD50B bind K-Ras and are recurrently deleted in human cancer. Nat Genet. 2016; 48(1): 53-58.

[10]	Lee S, Rauch J, Kolch W. Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. Int J Mol Sci. 2020; 21(3): 1102.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.